The purpose of this study is to evaluate the psychometric properties and utility of new, computerized, neurocognitive measures originally designed for non-human primates, in healthy control humans, humans with depression, and humans with depression undergoing electroconvulsive therapy (ECT). The benefits of the study outweigh the risk as there is the possibility of developing better computerized neurocognitive measures, and the risks are limited to no more than minimal test related fatigue and psychological stress.
At this time depressed individuals, and depressed individuals undergoing ECT (age 18-70) will be asked to participate in this study. After providing informed consent participants will undergo a clinical psychiatric evaluation to confirm the inclusion/exclusion criteria. After the clinical psychiatric evaluation, participants will complete common and new neurocognitive measures. There will be a total of two testing visits (baseline, 1 follow-up). For depressed, non-ECT participants, the follow-up visit will occur one-month post baseline. For depressed, ECT participants, the baseline will occur pre-ECT and the follow-up will occur post ECT course. Each study time point is expected to last 6 hours and will provide the participant with $50 compensation, for a total possible compensation of $100.
For more information, contact Anna Wise at 919-684-5939.